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Abst ract
Background and purpose: The aim of the study was to per-
form molecular analysis in a group of patients affected with
prion disease. Diagnosis was based on results of clinical and/or
histopathological examination of the brain. This is the largest
investigation of this type performed so far in Poland. 
Material and methods: Analysed material contained 36 cases
of prion disease, including 35 cases of Creutzfeldt-Jakob dise-
ase and one case of Gerstmann-Sträussler-Scheinker disease,
as well as two familial cases initially suspected of Hunting-
ton disease and Alzheimer disease. The control group consi-
sted of 87 subjects. The most frequent known mutations in
the PRNP gene were looked for, namely those in codons 102,
117, 178, 200, 217 and OPRI; the polymorphism Met/Val
in codon 129 was also analysed. The methods applied were
PCR-RFLP and DNA sequencing. 
Results: The following mutations were found: E200K in 
5 families, P102L in one family (previously identified), D178N
in one family and 6OPRI in one family. Overall, mutations
were detected in 17 persons (including 8 preclinical ones) from
8 pedigrees. Highly significant difference of codon 129 Met/Val
heterozygosity frequencies was found between the affected sub-
jects and the controls. Frequency of the familial form of prion
disease in the material analysed was 14%.
Conclusions: Screening for mutations in the PRNP gene 
should be performed in all diagnosed cases of prion disease and
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St reszc zenie
Wstêp i cel pracy: Celem pracy by³a analiza molekularna w gru-
pie osób dotkniêtych chorob¹ prionow¹, rozpoznan¹ na pod-
stawie objawów klinicznych i/lub wyniku badania neuropato -
logicznego mózgu. By³o to najwiêksze tego typu badanie
przeprowadzone dotychczas w Polsce. 
Materia³ i metody: W sk³ad analizowanego materia³u wesz³o
36 przypadków choroby prionowej, w tym 35 przypadków cho-
roby Creutzfeldta-Jakoba i jeden przypadek choroby Gerst-
manna-Sträusslera-Scheinkera, a tak¿e dwa przypadki rodzin-
ne podejrzane o chorobê Huntingtona i chorobê Alzheimera
oraz grupa kontrolna (87 osób). Poszukiwano najczêstszych
mutacji w genie PRNP: w kodonach 102, 117, 178, 200, 217
i OPRI. Kodon 129 analizowano równie¿ pod k¹tem zygo-
tycznoœci (walina/metionina). Stosowano metodê PCR-RFLP
i sekwencjonowanie. 
Wyniki: Wykryto mutacje: E200K – piêæ rodzin, P102L – jed-
na rodzina (wczeœniej zidentyfikowana), D178N – jedna rodzi-
na, 6OPRI – jedna rodzina. £¹cznie stwierdzono mutacjê 
w 8 rodowodach u 17 osób, w tym u 8 osób w fazie przedobja-
wowej. Zaobserwowano tak¿e bardzo istotn¹ ró¿nicê w czêsto-
œci wystêpowania heterozygotycznoœci Met/Val pomiêdzy grup¹
badan¹ i grup¹ kontroln¹. Czêstoœæ dziedzicznej postaci cho-
roby prionowej w analizowanym materiale wynosi 14%.
Wnioski: Mutacji w genie PRNP nale¿y poszukiwaæ we
wszystkich przypadkach choroby prionowej oraz w przypad-
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Introduction
Human prion diseases can be classified as the spo-
radic form, including the most common, Creutzfeldt-
Jakob disease (CJD); the familial form associated with
a mutation within the PRNP gene, which is inherited
as an autosomal dominant trait; and the acquired form,
including iatrogenic CJD, and CJD associated with the
intake of infected food, as in kuru (ritual cannibalism)
or in variant CJD (vCJD) transmitted through the con-
sumption of meat of cattle affected with bovine spongi-
form encephalopathy (BSE).  
Prion diseases manifest with subacutely progressive
dementia, cerebellar, pyramidal and extrapyramidal signs,
myoclonus and typical high-voltage rhythmic, and usu-
ally symmetrical discharges in electroencephalo graphy.
Pathological studies reveal mainly spongiform degene -
ration, neuronal loss, astrocytic gliosis, and specific de -
posits of the pathological prion protein PrPSc in nervous
tissue of the brain and the brainstem. The incidence of
the most common, sporadic CJD (sCJD) is estimated
to be 1: 1 000 000 per year in most countries worldwide.
The familial form of prion disease, which is respon-
sible for 10-15% of all cases [1,2], includes three clini-
cally distinct entities: familial CJD (MIM 123400), Ger-
stmann-Sträussler-Scheinker (GSS) (MIM 137440),
and fatal familial insomnia (FFI) (MIM 600072).
The pathological isoform of prion protein coded by
the PRNP gene is the infectious agent in prion diseases.
Pathological prion protein (PrPSc) features an altered
structure (conformation) and acts as a template for con-
version of the normal prion protein PrPC into the patho-
logical, infectious one [3].
The role of PrPC, although studied for a long time, is
unknown. Studies by Bounhar et al. [4] might suggest
that PrPC has some neuroprotective function. Experi-
men tal studies on mice suggested that the PrPC expres-
sion level affects neuronal differentiation [5]. Recently,
an experimental study in mice showed that PrPC expres-
sion in neurons plays a crucial role in maintenance of
the myelin sheath in peripheral nerves [6].
The PRNP gene is located on chromosome 20p12pter
[7] and contains two exons [8], while the whole reading
frame is comprised with the second, i.e. greater one. 
Codons 51-59 of the N-terminal domain contain
a region of five repeats; the first of them is a nonapep-
tide repeat and the four others are octapeptide ones. Mu -
tations within that region of PRNP are octapeptide in -
sertions. Owen et al. [9] were the first to describe that
type of mutation in 1989. Insertion of six octapeptide
repeats at the N-terminal of PrP was also the first docu-
 mented mutation within the PRNP gene. Point muta-
tions (more than 30 described so far) [10], causing the
familial form of the disease, are situated in the C-termi-
nal domain. It is noteworthy that the most common of
those mutations, A→G in codon 200, was identified for
the first time in a Polish family with CJD [11].
The most common mutations in the PRNP gene in -
clude E2000K, D178N, P102L, as well as OPRI, i.e.
the insertion of at least three octapeptide repeats after
codon 51. Additionally, it was shown that the Met/Val
polymorphism within codon 129 of the PRNP gene
markedly predisposes to the development of prion dis-
ease; it may also modify the age at onset of symptoms,
duration of the disease, and other phenotypic features of
the disease.
This study aimed at the molecular analysis of prion
disease cases diagnosed according to the clinical features
and/or histopathological brain studies performed in the
Institute of Psychiatry and Neurology between 2001 and
2010. The specific goals of this study included: (1) mo le-
 cular analysis of prion disease cases regarding the most
common mutations of the PRNP gene found in the fami l-
ial form of the disease; (2) pedigree analysis in familial cas-
in cases of familial occurrence of early onset dementia of unk-
nown aetiology. Families with identified mutations should be
offered genetic counselling and informed of risks of blood and
organs’ donation.
Key words: prion diseases, genetics, PRNP gene, mutations,
neuropathology.
kach rodzinnie wystêpuj¹cego otêpienia o wczesnym pocz¹tku
i niewyjaœnionej etiologii. Przebieg kliniczny i zmiany neuro-
patologiczne w niektórych przypadkach dziedzicznych chorób
prionowych mog¹ siê ró¿niæ od spotykanych najczêœciej w spo-
radycznej postaci choroby. Rodziny ze stwierdzon¹ mutacj¹ win-
ny byæ objête poradnictwem genetycznym i poinformowane
o zagro¿eniu zwi¹zanym z dawstwem krwi i narz¹dów do prze-
szczepienia.
S³owa kluczowe: choroby prionowe, genetyka, gen PRNP,
mutacje, neuropatologia.
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es of prion disease; (3) assessment of the relative frequen-
cy of familial and sporadic cases of prion disease in the
analysed material; (4) molecular analysis of the diagnosed
cases of prion disease regarding codon 129 polymorphism
– Met/Val heterozygosity, Met/Met homozygosity, and
Val/Val homozygosity – as well as their comparisons with
controls; (5) evaluation of the histopathological brain find-
ings in diagnosed cases of fa milial form, as well as com-
parison of brain pathology in deceased patients with the
sporadic versus familial form of prion disease.
Material and methods
Patients
This study included cases of prion disease diagnosed
clinically (denoted as probable cases) or confirmed with
histopathological examination of the brain (denoted as
definite cases). Materials was collected at the 1st Depart-
ment of Neurology, Institute of Psychiatry and Neurolo -
gy, between 2001 and 2010, based on the cooperation of
one of the authors (JK) with the Polish neurological wards
and departments. Patients were referred to the 1st Depart-
ment of Neurology, Institute of Psychiatry and Neurolo-
gy with suspected prion disease. The diagnosis was then
established according to the typical clinical features and/or
after the histopathological examination of the brain. In
some cases, the brains of patients who died were sent for
evaluation from other Polish departments. Definite cas-
es were those confirmed with brain histopathology. Prob-
able cases included those with typical clinical features,
observed at the 1st Department of Neurology, Institute 
of Psychiatry and Neurology or in other neurological
wards and departments. Within the last decade, a total of
240 cases (100%) were referred to the 1st Department of
Neurology, Institute of Psychiatry and Neurology for con-
sultations. Among those, 117 (49%) were diagnosed with
prion disease, including 63 probable cases diagnosed with
clinical features, and a further 54 definite cases confirmed
with neuropathological examination.
Histopathological features that led to the diagnosis 
of prion disease included grey matter spongiosis, astro-
cytic gliosis, neuronal loss and degeneration, and deposits
of pathogenic PrPSc in the brain (small deposits in vacuole
walls, perineuronal deposits, as well as deposits formed
into kuru plaques). Deposits of PrPSc were detected with
monoclonal antibodies (3F4 or, more recently, 1E4).
The probable diagnosis was made according to the
presence of the characteristic clinical syndrome of various
neurological abnormalities, often with cerebellar signs and
rapidly progressive dementia (usually of subacute course),
typical EEG abnormalities, presence of 14-3-3 protein in
cerebrospinal fluid (CSF) and magnetic resonance imag-
ing (MRI) features typical for spongious encephalopathy.
The sensitivity and specificity of the additional stud-
ies in the diagnosis of sporadic CJD is as follows: EEG,
66% and 74%, respectively [12]; brain MRI, 67% and
93%, respectively [13], protein 14-3-3 in CSF, 94% and
84%, respectively [12]. Combined probability of accu-
rate CJD diagnosis based on those three studies is esti-
mated to be 98%.
Control samples included anonymous DNA samples
isolated from healthy subjects (61 women and 26 men),
predominantly employees of the 1st Department of Neu-
ro logy, Institute of Psychiatry and Neurology.
DNA analysis
DNA samples isolated from the venous blood were
obtained from 36 patients diagnosed with prion disease.
This group was subjected to genetic analysis regarding 
(1) presence or absence of the most common PRNP
mutations typical for human prion disease, i.e. mutations
in codons 102, 117, 178, 200, 217, as well as OPRI; 
(2) PRNP gene codon 129 polymorphism. Cases sub-
jected to genetic analysis were divided into five subgroups
summarized in Table 1.
The sequence containing the open reading frame of
the PRNP gene was amplified with polymerase chain
reaction using an automated thermocycler (Perkin El -
mer), with the protocol described by Goldgaber et al.
[11]. The product (amplicon) was then digested in sep-
arate reactions with the restriction enzymes matched to
the analysed codons (Table 2).
Digestion products were separated on 2% agarose gel
with ethidium bromide. Amplicons with the altered pat-
tern of digestion bands were sequenced (commercial
sequencing performed by Genomed sp. z o.o.).
The results were analysed with Pearson chi-square
test within the statistical package Utility Programs for
Statistical Genetics, designed for the analysis of genetic
studies.
Results
Mutations were detected in 17 patients within 8 fam-
i lies affected with prion disease. Codon 200 mutation
(E>K) was found in 5 families. Codon 178 mutation
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(D>N), codon 102 mutation (P>L), and 6-octapep-
tide insertion (6OPRI) were found in one family each.
Testing of the first-degree relatives found mutations in
eight other subjects without clinical features of the dis-
ease (Table 3).
The genotype frequency of polymorphic codon 129
in controls was as follows: Met/Met 36.8%, Met/Val
54.0% and Val/Val 9.2% (allele frequency: Met 0.638
and Val 0.362). This is in agreement with the Hardy-
Weinberg law and does not differ significantly from the
frequencies found in Poland [14] or in other Caucasian
populations – British [9], French [15], American [16]
or Italian [17].
The genotype frequency in patients differed signifi-
cantly from controls and was as follows: Met/Met 85.7%
(24/28), Met/Val 10.7% (3/28), and Val/Val 3.6% (1/28)
(allele frequency: Met 0.9107 and Val 0.0893) (Table 4).
Figure 1 presents an example of the pedigree in fa -
milial prion disease caused by the 6OPRI mutation in
the PRNP gene.
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Categories of subjects examined No. of PRNP gene
persons Search for Examination  
mutations * of polymorphism 
in codon 129
Prion disease diagnosis based on histopathology of the brain 20 + +
(including one familial case of GSS reported previously, 
Kulczycki et al. [18])
Prion disease, diagnosis based on clinical picture, including 16 + +
second (not reported) familial case of GSS (the same family  
as mentioned above) 
Patients suspected of HD following exclusion of mutation  63 + np
inHTT gene
Patients suspected of monogenic form of AD 9 + np
Controls 87 np +
Table 1. Material of the study: Group of patients in whom searching for mutations in PRNP gene and determination of codon 129 polymorphism was performed 
GSS – Gerstmann-Sträussler-Scheinker disease; HD – Huntington disease; AD – Alzheimer disease. 
+ DNA analysis performed; np – DNA analysis not performed. 









Table 2. Restriction enzymes used for mutation detection in analysed codons
of PRNP gene
Pedigree No. Diagnosis Mutation Codon 129
1/I CJD E200K Met/Val
2/I Preclinical E200K Met/Val
3/I Preclinical E200K Met/Val
4/I Preclinical E200K Met/Met
5/I Preclinical E200K Met/Val
6/II CJD E200K Met/Val
7/II CJD E200K Met/Val
8/III CJD E200K Met/Met
9/IV CJD E200K Met/Met
10/V CJD* E200K Met/Val
11/VI GSS** P102L Met/Val
12/VII CJD** OPRI Met/Met
13/VIII CJD D178N Met/Met
14/VIII Preclinical D178N Met/Met
15/VIII Preclinical D178N Met-Met
16/VIII Preclinical D178N Met-Val
17/VIII Preclinical D178N Met-Val
Table 3. Mutations detected in 17 persons of 8 families
CJD – Creutzfeldt-Jakob disease, GSS – Gerstmann-Sträussler-Scheinker disease
* initially suspected of Huntington disease, ** a case of GSS reported in same family [18],
*** initially suspected of Alzheimer disease
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Neuropathological examination was carried out in
54 cases, but the genetic analysis was performed in 20
of them only (Table 1); we did not have DNA samples
of the other 34 subjects. This paper deals mostly with
genetic testing of PRNP mutations in familial cases.
Thus, we limit our report of the histological findings to
the characteristic or typical abnormalities found in some
hereditary prion diseases, especially in cases with codon
102 mutation (GSS case reported previously from our
centre, [18]) (Fig. 2), and in the first Polish case of
OPRI mutation (Fig. 3), reported previously in 2009
at the meeting of the Neuropathology and Neuroon-
cology Section, Committee of Neurological Sciences,
Polish Academy of Sciences (PAN) [19].
In both those cases, peculiar histological findings
included the distribution and shape of PrP deposits with-
in the brain structures, while the features of spongious
encephalopathy (spongiosis, neuronal loss, astrocytosis)
were all within the spectrum of the CJD picture.
The detailed analysis of clinical features in patients
affected with the familial form of prion disease is beyond
the scope of the paper. We would like to point out that
the age at onset of symptoms was advanced in most fa -
milial cases, and the duration of the disease was short,
similarly to the most common sporadic form of prion
disease. For example, in six cases of familial CJD with
E200K mutation identified in this study, mean age at
onset of symptoms was 59.7 years (range, 51-74 years).
It is noteworthy that within one of the reported families,
one sister (6/II) developed clinical symptoms at the age
of 51 (soon after head trauma with brain concussion),
Fig. 1. Pedigree with 6OPRI mutation, found in III-13 (see Table 3). The mutation was excluded in unaffected sister III-12. DNA samples from other family members
were not available. Course of the disease in 4 other affected subjects was similar to that in proband III-13
proband
affected persons, deceased
Codon 129 Affected Unaffected
polymorphism n (%) n (%)
Met/Met 31 (86.1%) 32 (36.8%)
Val/Val 1 (2.8%) 8 (9.2%)
Met/Val 4 (11.4%) 47 (54.0%)
Total 36 (100%) 87 (100%)
Table 4. Polymorphism of codon 129: Met/Met, Val/Val, Met/Val in group 





IV-1 IV-2 IV-3 IV-4 IV-5 IV-6 IV-7 IV-8 IV-9 IV-10 IV-11 IV-12
III-4 III-5 III-6 III-7 III-8 III-9 III-11 III-12III-10 III-13 III-14 III-15 III-16III-3
II-3 II-4 II-5 II-6 II-7 II-8
M      M  M       M
ins.
DNA
DNA – analysis of DNA performed
ins. – insertion of 144 nucleotides corresponding to 6-octapeptid (6 OPRI)
M/M – homozygosity – methionin/methionin of codon 129
DNA
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and the other one (7/II) developed the symptoms at the
age of 61 (Table 3); both sisters featured Met/Val hetero -
zygosity at codon 129.
A completely different clinical course of the dise -
ase was noted in patient 12/VII (Table 3), in whom the
6OPRI mutation (6-octapeptide insertion) was found.
He was previously suspected of having a monogenic
type of Alzheimer disease or other monogenic type of
dementia, which were all excluded by the team of C.
¯ekanowski (mutations in APP, PSEN1, PSEN2,
MAP1, PGRN1 genes were excluded). The patient
developed clinical symptoms at the age of 28, and died
at the age of 36 in terminal cachexia. The duration of
the disease was therefore 8 years. As suggested by the
family history of the three generations in that family, 
the clinical course was very similar in four other family
members, who were already deceased (Fig. 1). The pa-
tient’s mother, for example, developed clinical symptoms
at the age of 35, and died at 52. The disease lasted there-
fore 17 years. DNA samples were obtained from the pa -
tient (proband) and his healthy sister only.
Discussion
It is difficult to state clearly the prevalence of famil-
ial cases with PRNP mutation in Poland according to
such a small sample (DNA analysis of 36 cases). Af -
ter the exclusion of three pedigrees (V, VI, and VII)
(Table 3), suspected previously of having Huntington
or Alzheimer disease, and after the exclusion of a family
with a previously detected P102L mutation, the preva-
lence of mutations in the PRNP gene among studied
subjects is 14% (5/35). It is in agreement with the preva-
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Fig. 2. Deposits of PrP in the cerebellum in a case of Gerstmann-Sträussler-Scheinker disease. A) Multicentric (or confluent) deposits in granular layer of cerebellar cor-
tex. H&E staining,  approx. × 100; B) deposits of PrP in molecular layer of cerebellar cortex. Staining with monoclonal antibody 3F4, approx. × 100
A B
Fig. 3. Deposits of PrP in the cerebellum of the patient with 6OPRI mutation. Deposits situated only in molecular layer of cortex form stripes perpendicular to the sur-
face of cerebellum. Staining with monoclonal antibody 3F4. A) approx. × 100, B) approx. × 200
A B
Neurologia i Neurochirurgia Polska 2012; 46, 6 515
Hereditary form of prion disease in Poland
lence of 10-15% reported by other authors [1,2]. A parti -
cularly high percentage of familial prion disease (25.5%)
is noted in Hungary. It is assumed to be related to the
migration from Slovakia, where the prevalence of E200K
is particularly high [20]. 
In 2006, Mead put together 492 published cases;
according to his estimates, the most common PRNP
mutations worldwide are E200K, D178N, P102L, and
OPRI [10]. The commonest of those (> 70%) is E200K
mutation [21]. Our study brought a similar estimate:
E200K mutation was found in 5 out of 8 pedigrees with
a PRNP gene mutation.
As mentioned above, we detected 6OPRI mutation
(with 6-octapeptide insertion) in one pedigree. This
mutation is the most common one in the United King-
dom [9,10,22]. According to the data compiled by
Mead, median age at onset of the disease was 35 (range,
21-82) in 129 cases with more than three repeats. 
The median duration of the disease was 7 years, and
ranged between 3 months and 21 years [10]. This diver-
sity was related both to the number of octapeptide
repeats and to the zygosity at codon 129. According to
Poulter et al. [22], the heterozygosity Met/Val at that
codon was associated with the age at onset delayed for
about 10 years when compared with the homozygosity
Met/Met, which was also the genotypic combination
noted in our case (pedigree VII, Table 3, Fig. 1).
Both clinical features and neuropathological find-
 ings are very diverse. Features similar to our case 
(Fig. 3), including stripe-like deposits of PrPSc in the
granular layer of the cerebellum, were reported by Iron-
side (personal communicaton), and also by Vital et al. [23]
and King et al. [24], but only in cases with OPRI inser-
tions with less than 8 octa peptide repeats. It is interesting
that in cases with a small number of repeats (< 4), age at
onset was paradoxically more advanced, and the duration
of the disease was shorter [25]. This negative correlation
is explained by some authors with reference to the declin-
ing ability of the aging brain to degrade the assumed tox-
ic factor, possibly such as PrPSc [26].
Specific neuropathological features of a GSS case
within the same pedigree that was detected recently
(11/VI, Table 3) were described in 2001 [18] (Fig. 2).
In our pedigree, we detected P102L mutation of the
PRNP gene, which is the most characteristic mutation
for GSS. GSS may be, however, associated with other,
less frequently seen mutations within this phenotypic
variant of prion disease. In 2000, for example, Bra -
tosiewicz et al. [27] described a case of GSS with a nov-
el point mutation in codon M232T. This mutation is
in cluded in the schema of mutations related to ‘certain
or suspected pathogenicity’ published by Mead [10].
In one pedigree, we found D178N mutation in an
affected person (13/VIII, Table 3); age at onset was 
59 years. This mutation seems to be more prevalent than
the others in Germany [2] and particularly in Finland
[28]. This mutation was observed both in familial 
CJD and in FFI, even within the same pedigrees [29].
Among 72 cases reviewed by Mead, median age at onset
of symptoms in patients with the above-mentioned muta-
tion was 50 (range, 20-71), and the mean duration of the
disease was 11 months (range, 5 months – 4 years) [10].
The presence of mutation within the PRNP gene 
is not equivalent to being affected with the disease. Thus,
we deal with the incomplete penetrance of the mutated
gene. It is confirmed by observations that quite common-
ly (about 40%) prion disease occurs as an isolated case
(family history does not suggest presence of other affect-
ed family members) [30]. The incomplete penetrance of
the mutated gene might be attested by the single case
reports; e.g. E200K was found in a 75-year-old mother of
a patient affected with CJD in Slovakia [31]. Goldfarb 
et al. [32] estimated the penetrance of the most common
E200K mutation to be 0.56. According to Chapman et al.
[33], cumulated penetrance among Libyan and Tunisian
Jews was 50% at the age of 60, and 80% at the age of 80.
Our sample contained eight subjects, mutation carri-
ers, who are healthy so far (Table 3), but it cannot be con-
sidered as proof of the incomplete penetrance of the mutat-
ed gene, as the majority of those subjects did not reach the
age associated with the highest risk of incident disease.
From the clinical point of view, diagnosis of demen-
tia of unknown aetiology is the major issue related to the
genetics of prion diseases. We highlight the fact that two
cases in our sample were patients with previously sus-
pected Huntington or Alzheimer disease. This is not an
exception. A family with Huntington disease-like disor-
der (MIM 603218) was described, with the autosomal
dominant pattern of inheritance, and symptomatology
that included dementia, dysarthria and ataxia, but also
choreiform involuntary movements and atrophy of the
basal ganglia [34]. A case of familial CJD with a long
duration of the disease, initially thought to be Alzheimer
disease, and finally diagnosed with the 6OPRI mutation
(12/VII, Table 3, Fig. 1), is also very instructive. Unusu-
al neuropathological findings in that case might be con-
sidered as typical for OPRI mutations (Fig. 3) but only
in cases with insertions of a specific number of octapep-
tide repeats [23,24]. Early onset of symptoms in that
patient might be related to the Met/Met homozygosity
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at codon 129. The patient’s mother, very probably affect-
ed with the same disease, developed symptoms later in
her life and the disease lasted even longer, which might
be related to the heterozygosity at codon 129.
Finckh et al. [35] performed genetic testing in 36 pa-
tients with early onset familial dementia. Their analysis
included PSEN1, PSEN2, APP and PRNP genes.
Mutations were found in 12 cases, and were related to
PRNP in 4 cases (one-third). We support the view of
Malluci et al. [36], who suggested that “indeed, inher-
ited prion disease should be excluded in any individual
presenting with atypical presenile dementia or neu-
ropsychiatric features and ataxia, including suspected
cases of new variant CJD”.
We have already mentioned that the polymorphism
of Met and Val at codon 129 greatly influences suscep-
tibility to the disease and modifies its clinical picture.
Similarly to other studies, the difference between patients
and controls is striking (Table 4). It cannot be exclud-
ed that besides genotype (type of mutation and poly-
morphisms), some environmental factors also affect the
time of disease onset. It may be suggested by the great
difference of age at onset between two sisters affected
with E200K mutation (6II and 7II in Table 3). The one
that had earlier onset of symptoms suffered from a major
head injury shortly before the beginning of symptoms.
Genetic counselling is a major issue in genetic test-
ing of prion diseases. In particular, it should include
families with PRNP gene mutations detected with mol-
ecular studies. According to our experience, not all sub-
jects who are at high risk of having a mutated gene
decide to have such studies performed, while the results
of testing might enable the appropriate prophylactic
measures to avoid transmission of the disease to subse-
quent generations. According to the accepted bioethical
principles, any decision made by the members of fami-
lies at risk of inherited prion disease should be accept-
ed. Each adult has the right to know whether he or she
inherited the causative gene, but could decline testing
as well, at least in the case of incurable disease.
The peculiar aspect of genetic counselling in rela-
tion to inherited prion diseases is the infectiousness of
the pathological form of prion protein PrPSc. Healthy
persons with a diagnosed PRNP gene mutation or those
who are at risk of prion disease but who did not consent
to genetic testing should be informed that they can be
neither blood donors nor organ donors. Ostrowski [37]
raised that problem in his monograph related to the
transmission of disease through transplants. At the end
of the special conference dedicated to that problem, he
concluded: “we should resign from donors who were
affected with the subacute encephalitis when alive, as
well as from those in whose families Creutzfeldt-Jakob
disease or other prion disease was diagnosed” [38].
Conclusions
1. Fourteen percent of the 36 analysed cases of prion dis-
ease were familial cases caused by mutations within the
PRNP gene. Other cases were probably sporadic ones.
2. Mutation at codon 200 within the PRNP gene was
the most commonly detected mutation (5 out of 8 pe -
digrees with the detected mutation). This is in agree-
ment with observations made in other countries.
3. As expected, homozygosity Met/Met and Val/Val is
significantly more common in patients with prion dis-
ease than in controls. It is valid especially in sporadic
cases of the disease. This confirms the protective role
of codon 129 heterozygosity and suggests the impor-
tance of that polymorphism in the pathogenesis of
human prion disease.
4. The course of familial prion disease might differ wide-
ly from the most common sporadic disease, which is
attested by the early onset of the disease in some patients
and by the long duration of the disease in one of the
analysed cases with 6OPRI mutation in the PRNP gene.
5. The diagnosis of prion disease should be considered
in familial occurrence of neurological disorders with
dementia, especially in cases with early onset of symp-
toms, as suggested by two familial cases, initially 
suspected of Huntington disease and monogenic form
of Alzheimer disease, in whom mutations in the
PRNP gene were found.
6. Histopathological findings in brains of patients affect-
ed with the familial form of prion disease might be
divergent from those typical for the sporadic form. This
may be associated with the characteristics of particular
mutations in the PRNP gene and with prolonged,
long-term course of the disease in some familial cases.
7. Genetic counselling is a major issue in prion diseases.
Families with detected mutations in the PRNP gene
should be informed that the carriers of those muta-
tions are not allowed to be donors of blood or organs
for transplantations.
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